With its launch barely three years in the rearview mirror, Remix Therapeutics Inc. has inked its second potential $1 billion pharma collaboration, drawing Roche Holding AG to the table with the promise of its RNA processing platform and the potential to develop small-molecule therapeutics targeting the underlying drivers of disease. At the same time, the Watertown, Mass.-based firm added $60 million in a venture round, bringing its total financing to date to $201 million.
Allorion Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor.
Incheon, South Korea-based Celltrion Inc. said on Jan. 2 that it reached an agreement with Asian health care investment firm CBC Group to partially sell off its Primary Care unit by March 2024 for ₩209.9 billion (US$160.7 million). Incheon, South Korea-based Celltrion Inc. said on Jan. 2 that it reached an agreement with Asian health care investment firm CBC Group to partially sell off its Primary Care unit by March 2024 for ₩209.9 billion (US$160.7 million).
Lianbio Co. Ltd. is out-licensing NBTXR-3 to Janssen Pharmaceutical NV to develop and commercialize the radioenhancer in China, South Korea, Singapore and Thailand. Earlier this month, Tang Capital’s Concentra Biosciences LLC lodged a proposal to acquire Lianbio for $465 million, which the company’s shareholders rejected.
South Korean biotech Pinotbio Co. Ltd. inked a $250 million (₩320 billion) licensing deal with Princeton, N.J.-based Conjugatebio Inc. to develop 10 antibody-drug conjugate (ADC) targets with Pinotbio’s ADC platform technology. The deal announced on Dec. 21 adds to a previous agreement between the two companies last year. Pinotbio and Conjugate first teamed up to discover and develop five ADC targets in June 2022.
The spate of recent deals involving antibody-drug conjugates (ADC) continues in a field composed of record-breaking agreements in 2023. The newest of the deals were focused on Asia. GSK plc entered a license deal for the exclusive rights for clinical development and commercialization of Hansoh Pharmaceutical Co. Ltd.’s B7-H3-targeted ADC, HS-20093. Also, South Korea’s Dong-A ST Co. Ltd. is expanding into the ADC space by acquiring Abtis Co. Ltd. and its Abclick platform for ADC drug development.
Legochem Biosciences Inc. signed a $1.7 billion licensing deal with Janssen Biotech Inc. for its Trop2-directed antibody-drug conjugate (ADC), closing the biggest technology transfer deal in Korean biotech history after Chong Kun Dang Pharmaceuticals Corp.
Elpiscience Biopharma Ltd. is out-licensing to Astellas Pharma Inc. two preclinical bispecific macrophage engagers – ES-019, an anti-PD-L1/SIRPα bispecific antibody, and another unnamed program – in a deal worth up to $1.7 billion. The deal marks the Shanghai-based company’s first out-licensing deal, Elpiscience CEO Darren Ji told BioWorld, noting that Astellas will have global rights to both molecules with a potential to in-license two more.
Allorion Therapeutics Inc. could receive $40 million in up-front and near-term payments from Astrazeneca plc in the companies’ exclusive option and global license deal. The two plan to develop and commercialize an L858R mutated allosteric inhibitor for treating EGFR inhibitor-mutant non-small-cell lung cancer.
Nearly two years after Novartis AG signed a $1.7 billion deal for options to Voyager Therapeutics Inc.’s adeno-associated virus capsids for central nervous system disorders, the Basel, Switzerland-based company secured rights to develop gene therapies for Huntington’s disease and spinal muscular atrophy in a licensing agreement potentially worth $1.3 billion.
RSS
